(19)
(11) EP 4 798 206 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24805292.0

(22) Date of filing: 24.10.2024
(51) International Patent Classification (IPC): 
A61K 31/519(2006.01)
A61P 17/06(2006.01)
 A61P 17/04(2006.01)
A61K 45/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/519; A61P 17/04; A61P 17/06; A61K 45/06
 
C-Sets:
A61K 31/519, A61K 2300/00;
(86) International application number:
PCT/US2024/052716
(87) International publication number:
WO 2025/090702 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 25.10.2023 US 202363593108 P
06.12.2023 US 202363606912 P
23.09.2024 US 202463697819 P

(71) Applicant: Principia Biopharma Inc.
Morristown, NJ 07960 (US)

(72) Inventors:
  • BARET-CORMEL, Lydie
    75017 Paris (FR)
  • MANNENT, Leda
    75017 Paris (FR)
  • MIKOL, Vincent
    75017 Paris (FR)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) RILZABRUTINIB FOR USE IN THE TREATMENT OF ITCH ASSOCIATED WITH ATOPIC DERMATITIS AND/OR PRURIGO NODULARIS